BridgeBio Pharma Inc. BBIO on Wednesday announced a recent presentation of interim results from its Phase 3 FORTIFY trial for BBP-418, a treatment for limb-girdle muscular dystrophy type 2I/R9.

The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. ・Capricor is now awaiting the U.S. Food and Drug ...

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...

Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...

BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, ...

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, affecting 12%–13% of adolescents in the United States, according to some studies. The pattern of inattention, ...

New research suggests GLP-1 drugs may increase the risk of bone and tendon injuries and other conditions, including ...

The study found that people taking PPIs had a much higher likelihood of reporting several serious kidney conditions. These ...

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

For more information, please visit www.nmdpharma.com.

A new study suggests that combining two medicines may help people lose a large amount of weight while protecting their muscles at the same time. The research looked at a treatment that uses ...

SMA newborn screening may help infants start treatment sooner, which researchers say could support better motor development outcomes.